NewsBenzinga카지아 테라퓨틱스, 소바젠이 뇌전증 치료제 파사리십의 1b/2a상 임상시험에서 첫 번째 참가자 투여 발표 카지아 테라퓨틱스, 소바젠이 뇌전증 치료제 파사리십의 1b/2a상 임상시험에서 첫 번째 참가자 투여 발표 Benzinga 2026.09.22 11:33 (GMT+0) Open on Benzinga Other news Tennant: An Overvalued Dividend King Facing Margin Pressures (NYSE:TNC) Parker-Hannifin Stock: Wall Street Is Paying Too Much For Quality (NYSE:PH) DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives Kevin O'Leary Says This Is What Sets Elon Musk Apart: 'He Does Not Deal With Noise' Grab Holdings Stock: Strong Multiple-Year Growth Ahead (NASDAQ:GRAB) Ladder Capital Stock: The Case For An Upside Revaluation (NYSE:LADR)
